Shares of Mesoblast Limited (NASDAQ:MESO - Get Free Report) traded up 7.9% on Wednesday . The stock traded as high as $5.16 and last traded at $5.06. 196,286 shares changed hands during trading, a decline of 90% from the average session volume of 1,913,120 shares. The stock had previously closed at $4.69.
Analyst Upgrades and Downgrades
A number of brokerages have commented on MESO. StockNews.com cut Mesoblast from a "hold" rating to a "sell" rating in a research note on Tuesday, April 2nd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Mesoblast in a report on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, Mesoblast currently has a consensus rating of "Hold" and a consensus price target of $13.67.
View Our Latest Analysis on MESO
Mesoblast Stock Performance
The stock has a market capitalization of $571.49 million, a P/E ratio of -4.47 and a beta of 3.60. The stock has a 50-day moving average price of $3.25 and a two-hundred day moving average price of $2.58.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. State Street Corp bought a new stake in Mesoblast in the first quarter worth $757,000. BlackRock Inc. boosted its holdings in shares of Mesoblast by 20.8% during the 1st quarter. BlackRock Inc. now owns 864,638 shares of the company's stock valued at $3,649,000 after acquiring an additional 149,023 shares during the last quarter. Millennium Management LLC bought a new stake in Mesoblast during the fourth quarter valued at approximately $344,000. Prosperity Wealth Management Inc. bought a new stake in shares of Mesoblast during the 3rd quarter valued at $79,000. Finally, Jane Street Group LLC bought a new stake in Mesoblast during the fourth quarter valued at about $187,000. 1.43% of the stock is currently owned by institutional investors.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Further Reading
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
